Screening for the study suggests that around 38% of patients with gastric or GEJ adenocarcinomas have tumours that express the claudin 18.2 biomarker in more than 75% of their cells, the threshold ...

The findings could guide future efforts to stimulate the regeneration of sensory hearing cells ... The Maternal Microbiome During Pregnancy Impacts Offspring's Stem Cells in Mice Dec. 11 ...

The findings could guide future efforts to ... Dec. 12, 2024 — Scientists have discovered that our specialized immune cells, called T cells, are what they eat -- their switch from functional to ...

The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

Claudin 18.2 is a biomarker positively expressed ... the molecule is usually located within tight junctions that connect cells and isn't typically found in other tissues. After cancer develops ...

It feels like the Splinter Cell remake has been on its way for a while now, which isn't helped by the fact it's been over two years since we heard anything official about the game. From what we've ...

ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).

Cell biology is the discipline of biological sciences that studies the structure, physiology, growth, reproduction and death of cells. Research in cell biology uses microscopic and molecular tools ...

Our lead candidate, EO-3021, is a potential best-in-class, Claudin 18.2 ADC and is currently being evaluated in the dose expansion ... HER3 is a protein expressed across several types of solid tumors, ...

T cells are white blood cells that are important for adaptive immunity. They have unique cell surface receptors that are generated by randomly assorting genes. These receptors allow T cells to ...

Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT ...